

**Date: November 27, 2025**

To,  
National Stock Exchange of India Limited  
BSE Limited  
Symbol: NSE: GRANULES: BSE: 532482

Dear Sir/Madam,

**Sub: Intimation for Incorporation of Granules Pharmaceuticals Canada, Inc., a wholly-owned step-down foreign subsidiary of the Company.**

**Ref: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.**

---

With reference to the captioned subject, we wish to inform that M/s. Granules Pharmaceuticals, Inc., a Wholly Owned foreign subsidiary of the Company, has incorporated a Wholly Owned Subsidiary (WOS), namely “**Granules Pharmaceuticals Canada, Inc.**” in Canada on November 26, 2025.

In terms of the Listing Regulations read with the SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 on Disclosure of material events/information, we are furnishing herewith the details in the enclosed **Annexure**.

We request you take the above information on record.

Thanking You.

**For GRANULES INDIA LIMITED**

**CHAITANYA TUMMALA**  
**(COMPANY SECRETARY &**  
**COMPLIANCE OFFICER)**  
Encl: As above



---

**REGISTERED OFFICE**

**Granules India Limited**

CIN: L24110TG1991PLC012471

15<sup>th</sup> Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India

Contact Us: Tel: +91 40 69043500 | Fax: +91-40-23115145 | mail@granulesindia.com

[www.granulesindia.com](http://www.granulesindia.com)

**Annexure I**

**Disclosure under Part A Para A(i) of Schedule III read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

S. No.	Particulars	Description
1.	Name of the target entity, details in brief such as size, turnover etc.	Granules Pharmaceuticals Canada, Inc. is a wholly owned subsidiary of "Granules Pharmaceuticals, Inc."  It is a newly incorporated Company and has not commenced its business.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired. If yes, the nature of interest and details thereof and whether the same is done at "arms-length"	No
3.	The industry to which the entity being acquired belongs	Prescription pharmaceuticals      Generic
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of the target entity, if its business is outside the main line of business of the listed entity)	Incorporated by Granules Pharmaceuticals, Inc.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable.
6.	The indicative time period for completion of the acquisition	Not applicable
7.	Nature of consideration- whether cash consideration or share swap and details of the same.	Not applicable
8.	Cost of acquisition or the price at which the shares are acquired	Not applicable
9.	Percentage of shareholding/control acquired and/or number of shares acquired	Granules Pharmaceuticals, Inc. will hold 100% of the equity capital in Granules Pharmaceuticals Canada, Inc.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of the last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Granules Pharmaceuticals Canada, Inc. is incorporated in Canada.  It is a newly incorporated Company and has not commenced its business.

